Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience
Switching biologics for CRSwNP is frequent in Canadian rhinology practices, with 16% of patients switching at least once. The most common switch is from mepolizumab to dupilumab with inadequate CRSwNP control driving this switch. This study may help guide sequential or simultaneous use of biologics in CRSwNP patients.
Authors
- Masih Sarafan
- Doron D. Sommer (ORCID: https://orcid.org/0000-0001-9692-7414)
- Yaser Ammar (ORCID: https://orcid.org/0000-0002-6427-9245)
- Andrew Thamboo (ORCID: https://orcid.org/0000-0002-3910-2253)
- Béatrice Voizard (ORCID: https://orcid.org/0000-0002-3937-3248)
- Paul J. MacInnis
- James P. Nugent (ORCID: https://orcid.org/0000-0001-9631-8600)
- Karen Chalmers
- Juan Carlos Hernaiz‐Leonardo (ORCID: https://orcid.org/0000-0002-3013-2683)
- Yvonne Chan (ORCID: https://orcid.org/0000-0002-8502-3214)
- Marisa Dorling (ORCID: https://orcid.org/0009-0003-2393-0753)
- John Lee
- Arif Janjua (ORCID: https://orcid.org/0000-0002-7420-3236)
Institutions
- University of British Columbia (CA)
- University of Toronto (CA)
- McMaster University (CA)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1002/alr.23466
- Citations
- 9
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 5.22